Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1964 1
1999 1
2013 1
2015 1
2017 1
2018 2
2019 3
2020 2
2021 3
2022 9
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Results by year

Filters applied: . Clear all
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Reply to W. Altundag.
Audeh W. Audeh W. JCO Precis Oncol. 2022 Aug;6:e2200315. doi: 10.1200/PO.22.00315. JCO Precis Oncol. 2022. PMID: 35952323 No abstract available.
Changing Landscape of Clinical-Genomic Oncology Practice.
Trivedi H, Kling HM, Treece T, Audeh W, Srkalovic G. Trivedi H, et al. Among authors: audeh w. Acta Med Acad. 2019 Apr;48(1):6-17. doi: 10.5644/ama2006-124.238. Acta Med Acad. 2019. PMID: 31264429 Free article.
BluePrint breast cancer molecular subtyping recognizes single and dual subtype tumors with implications for therapeutic guidance.
Kuilman MM, Ellappalayam A, Barcaru A, Haan JC, Bhaskaran R, Wehkamp D, Menicucci AR, Audeh WM, Mittempergher L, Glas AM. Kuilman MM, et al. Among authors: audeh wm. Breast Cancer Res Treat. 2022 Oct;195(3):263-274. doi: 10.1007/s10549-022-06698-x. Epub 2022 Aug 19. Breast Cancer Res Treat. 2022. PMID: 35984580 Free PMC article.
Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy.
Whitworth PW, Beitsch PD, Murray MK, Richards PD, Mislowsky A, Dul CL, Pellicane JV, Baron PL, Rahman RL, Lee LA, Dupree BB, Kelemen PR, Ashikari AY, Budway RJ, Lopez-Penalver C, Dooley W, Wang S, Dauer P, Menicucci AR, Yoder EB, Finn C, Blumencranz LE, Audeh W. Whitworth PW, et al. Among authors: audeh w. JCO Precis Oncol. 2022 Sep;6:e2200197. doi: 10.1200/PO.22.00197. JCO Precis Oncol. 2022. PMID: 36108259 Free PMC article.
Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Whitworth PW, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Murray MK, Gittleman MA, Budway RJ, Rahman RL, Kelemen PR, Dooley WC, Rock DT, Cowan KH, Lesnikoski BA, Barone JL, Ashikari AY, Dupree BB, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W; NBRST Investigators Group. Whitworth PW, et al. Among authors: audeh w. JCO Precis Oncol. 2022 Apr;6(1):e2100463. doi: 10.1200/PO.21.00463. JCO Precis Oncol. 2022. PMID: 35476550 Free PMC article.
22 results